In this episode of The GLP-1 Podcast Show, I speak with Dr. Michael Nauck, Head of Clinical Research at the Diabetes Division of St. Josef-Hospital, Ruhr-University Bochum, Germany. We explore the early discoveries behind incretin hormones, the development of GLP-1–based therapies, and their expanding role in diabetes, obesity, and cardiovascular care. Dr. Nauck also discusses the next generation of dual and triple agonists shaping obesity medicine. Listen now on all major platforms.

“For the first time, weight loss medications, like GLP-1, achieved meaningful reductions without serious safety concerns.”

Meet the guest: Dr. Michael Nauck is Head of Clinical Research at the Diabetes Division, St. Josef-Hospital, Ruhr-University Bochum, Germany. His pioneering work on incretin hormones established the scientific foundation for GLP-1–based therapies in type 2 diabetes. With a research focus on metabolic regulation and cardiovascular outcomes, Dr. Nauck continues to advance innovation in endocrinology and obesity care.

What you will learn:

• (00:00) Highlight
• (01:09) Introduction
• (02:18) Incretin effect explained
• (06:38) Early GLP-1 discoveries
• (08:39) DPP-4 inhibitors’ role
• (12:12) Beyond glucose control
• (16:44) Mechanisms of GLP-1
• (22:51) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The GLP-1 Podcast Show

Instagram: The GLP-1 Podcast Show

LinkedIn: The GLP-1 Podcast Show

The GLP-1 Podcast Show is a new podcast created to spotlight the science, perspectives, and leaders shaping the future of obesity treatment and metabolic medicine. In this first episode, we welcome Dr. Michael Schwartz, Robert H. Williams Endowed Chair and Professor of Medicine at the University of Washington, who speaks with Areesha Moiz about how GLP-1 receptor agonists reshape obesity treatment. The discussion covers adaptive responses to weight loss, brain regulation of appetite, mechanisms of long-acting drugs, and the challenges of sustaining results after treatment withdrawal. It also highlights emerging therapeutic strategies to prolong weight loss. Listen now on all major platforms!

"GLP-1 receptor agonists are unique because they continuously and maximally activate their target, creating effects that natural peptides could never achieve."

Meet the guest: Dr. Michael Schwartz received his MD from Rush Medical College and trained in endocrinology and metabolism at the University of Washington. He is internationally recognized for his research on brain mechanisms controlling body weight, glucose homeostasis, obesity, and diabetes. A recipient of numerous awards, Dr. Schwartz has published nearly 300 papers and directed major research institutes in Seattle.

What you will learn:

• (00:00) Highlight
• (01:15) Introduction
• (03:26) GLP-1 drug design
• (07:51) Appetite regulation
• (10:23) Adaptive response
• (14:39) Weight regain
• (17:55) Maintenance strategies
• (24:44) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The GLP-1 Podcast Show

Instagram: The GLP-1 Podcast Show

LinkedIn: The GLP-1 Podcast Show

A whole new era of communication in GLP-1 is here!

Now you’ve got the sharpest minds in GLP-1 research right in your pocket. What’s best?

You can listen to them while driving to the hospital, walking between labs, traveling, or just running errands. Now it’s never been this good or this simple.

Welcome to The GLP-1 Podcast Show, a monthly podcast where you’ll hear cutting-edge perspectives and what’s working in the world of GLP-1.

Our aspiration is to be the first place you are going to go to find out what's happening, the latest breakthroughs, clinical updates, and innovations in GLP-1 care and research.